Tesamorelin and the Aging Brain: One Trial, Many Questions

At a Glance

Why growth hormone and the brain come up together

Growth hormone release falls with age, and so does its downstream messenger, IGF-1. Both have receptors in the brain, and in animal studies the somatotropic axis influences synaptic function and brain metabolism. It is a natural idea, then, that restoring the signal might help an aging brain.

There is also a strong counter-argument, and anyone interested in longevity should hear it. People with inherited growth hormone receptor deficiency (Laron syndrome) in an Ecuadorian cohort had markedly lower rates of cancer and diabetes than their unaffected relatives (Guevara-Aguirre 2011). Lower growth hormone signalling is not obviously bad for healthy lifespan. “Restore youthful GH levels” is therefore a hypothesis with real risks attached, not an obvious goal.

What tesamorelin is

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), the hypothalamic peptide that tells the pituitary to release growth hormone. Because it acts upstream, growth hormone is still released in pulses and remains under the body’s own feedback control. That is the main pharmacological difference from injecting growth hormone itself.

Its approval rests on trials in HIV-associated lipodystrophy, where it reduced visceral abdominal fat compared with placebo (Falutz 2007).

The brain evidence

The 2012 randomised trial

Baker and colleagues ran the key study (Baker 2012):

• Who: 152 adults aged 55 to 87 (mean 68), 66 of them with mild cognitive impairment (MCI).
• What: daily injections of tesamorelin or placebo for 20 weeks, then a 10-week washout.
• Cognition: the tesamorelin group did better on a cognitive composite in the intention-to-treat analysis, with a similar effect in healthy older adults and in MCI. The clearest gain was in executive function; verbal memory showed only a trend.
• Physiology: IGF-1 roughly doubled (still within the physiological range), body fat fell, and fasting insulin rose within the normal range.

This was a well-designed, placebo-controlled trial. It is also a single trial, of moderate size, with a short treatment period and a composite cognitive outcome rather than a clinical endpoint such as conversion to dementia.

The imaging substudy

A magnetic resonance spectroscopy substudy of the same trial found that tesamorelin raised GABA, the brain’s main inhibitory neurotransmitter, in all three regions measured, raised NAAG in the frontal cortex and lowered myo-inositol in the posterior cingulate (Friedman 2013). The authors found no significant association between these chemical changes and the cognitive changes. It is a plausible mechanism, not a confirmed one.

What has happened since

As far as I can find, no larger confirmatory trial of tesamorelin for cognition in older adults has been published in the 14 years since. A 2025 trial in people with HIV, abdominal obesity and neurocognitive impairment compared tesamorelin with standard care: waist circumference fell, but cognitive change did not differ between groups (Ellis 2025). That study had no placebo arm and limited power, so it does not refute the 2012 result. It does not support it either.

Preclinical vs human evidence

Approved analogue vs unapproved secretagogues

Tesamorelin often gets lumped together with CJC-1295, ipamorelin, sermorelin and MK-677 in online “GH peptide stacks”. The difference matters:

• Tesamorelin has phase 3 data and an FDA approval in one indication, and is manufactured under pharmaceutical standards.
• Sermorelin was once FDA-approved in children with growth hormone deficiency; the branded product was discontinued in the US in 2008.
• CJC-1295, ipamorelin and similar compounds are not approved anywhere.

See CJC-1295/ipamorelin vs tesamorelin and sermorelin vs CJC-1295 for the comparison.

Safety

Based on the trials and the US product information:

• IGF-1 rises. This is the intended effect, and the reason for the main long-term question: whether years of higher IGF-1 change cancer risk in older people. Active malignancy is a contraindication in the US label.
• Glucose metabolism. Fasting insulin rose in the Baker trial (Baker 2012); glucose intolerance is a labelled warning, which matters for anyone with prediabetes.
• Fluid retention, joint pain and injection-site reactions are listed side effects.
• Pregnancy is a contraindication.
• Non-pharmaceutical sources of “tesamorelin” sold as research peptides carry identity, purity and sterility risks that no trial has tested.

Dosing

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

• Approved dose (US label, HIV-associated lipodystrophy). The three US formulations are dosed differently because they deliver different exposure. The original Egrifta (1 mg vials) was given as 2 mg subcutaneously once daily. Egrifta SV (2 mg vial) is 1.4 mg subcutaneously once daily, which gives exposure similar to the 2 mg Egrifta dose (Egrifta SV label, DailyMed). Egrifta WR (11.6 mg vial, mixed weekly) is 1.28 mg subcutaneously once daily (Egrifta WR label, DailyMed). All are injected into the abdomen with rotating sites.
• Dose in the cognition trial. Participants self-injected tesamorelin 1 mg subcutaneously once daily, 30 minutes before bedtime, for 20 weeks (Baker 2012). That is half the original Egrifta label dose. IGF-1 rose by 117% on this dose and stayed within the physiological range.

Using tesamorelin for brain aging is off-label. It should only happen within a clinical trial or with a physician who explains the evidence and monitors IGF-1 and glucose.

Regulatory status

Where this leaves a worried patient

If memory or concentration is slipping, the useful first steps are a proper assessment, treatment of vascular and metabolic risk factors, hearing and sleep, and the lifestyle measures with trial evidence. These are covered in brain aging and cognitive reserve. For a structured clinical work-up of memory complaints, the Douwes Brain Center describes its approach on its mild cognitive impairment page Douwes Brain Center ↗.

Tesamorelin remains an interesting research lead. I would like to see the 2012 result tested in a larger, longer trial with clinical endpoints and careful safety monitoring before it is offered for brain aging.

Limitations of this review

• The cognitive evidence rests on one trial and one substudy from the same group.
• The 2025 HIV trial studied a different population and design.
• Product labels and regulatory decisions may change; check the current US label for the full safety information.

Related reading

• Nootropic peptides: an evidence guide
• Semax
• GLP-1 receptor agonists through a geroscience lens
• Brain aging and cognitive reserve